Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01094262 · ClinicalTrials.gov registry record · Phase 2
A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis
A Phase 2 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Terminated
- Registry status
- Phase 2
- Development phase
- 196
- Enrollment target
NCT01094262 is a Phase 2 study that was terminated before completion, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 196 participants.
The verdict
NCT01094262, a Phase 2 study, was terminated before completion, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 196 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate pain relief, safety, and tolerability of a new treatment (JNJ-42160443) for moderate to severe pain of osteoarthritis of the knee in comparison to a standard pain treatment and placebo.
Interventions
- DRUG Placebo
- DRUG JNJ-42160443
- DRUG Oxycodone CR (standard pain medication)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2010-04-20 |
| Est. Completion | 2011-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01094262
The ClinicalTrials.gov registry entry for NCT01094262 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01094262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01094262 about?
NCT01094262 is a clinical study titled "A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis". The purpose of this study is to evaluate pain relief, safety, and tolerability of a new treatment (JNJ-42160443) for moderate to severe pain of osteoarthritis of the knee in comparison to a standard pain treatment and placebo.
What is the current status of trial NCT01094262?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 196 participants. The study started on 2010-04-20. Estimated completion is 2011-07-01.
What interventions are being tested in trial NCT01094262?
The interventions under investigation include: Placebo (DRUG), JNJ-42160443 (DRUG), Oxycodone CR (standard pain medication) (DRUG).
Who is sponsoring clinical trial NCT01094262?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.